Revenue Breakdown
Composition ()
No data
Revenue Streams
Immunocore Holdings PLC (IMCR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue, accounting for 96.6% of total sales, equivalent to $62.91M. Another important revenue stream is Genentech. Understanding this composition is critical for investors evaluating how IMCR navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Immunocore Holdings PLC maintains a gross margin of 99.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6.92%, while the net margin is -0.17%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IMCR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IMCR competes directly with industry leaders such as SNDX and GLUE. With a market capitalization of $1.64B, it holds a significant position in the sector. When comparing efficiency, IMCR's gross margin of 99.51% stands against SNDX's 95.42% and GLUE's 100.00%. Such benchmarking helps identify whether Immunocore Holdings PLC is trading at a premium or discount relative to its financial performance.
